Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients with Newly Diagnosed Multiple Myeloma
Annals of Hematology(2025)
Key words
Subcutaneous,Daratumumab,Multiple myeloma,Autologous stem cell transplant,Real-world
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined